Immunotherapy has garnered an important place in the therapeutic landscape of treatment in prostate cancer since approval of sipuleucel-T.
Ipilimumab is a checkpoint inhibitor that is currently approved for the treatment of advanced melanoma. In the June issue of Lancet Oncology, Kwon and colleagues report the phase III trial using ipilimumab in a post-docetaxel metastatic castration-resistant prostate cancer population. While the primary endpoint of overall survival was not met, several lessons are learned from the analysis of this trial. Perhaps better refinement of a more favorable group of patients who may potentially benefit from an immunologic treatment should be advocated.
Written by:
Kittai A, Meshikhes M, Aragon-Ching JB. Are you the author?
Department of Internal Medicine; George Washington University Medical Center; Washington, DC USA; Department of International Medicine Programs; George Washington University; Washington, DC USA; Division of Hematology/Oncology; Department of Medicine; George Washington University Medical Center; Washington, DC USA.
Reference: Cancer Biol Ther. 2014 Oct 1;15(10):1299-300.
doi: 10.4161/cbt.29928
PubMed Abstract
PMID: 25046606
UroToday.com mCRPC Treatment Section
